First UK experience of BTK inhibitor PCI-32765-dramatic responses in relapsed/refractory mantle cell lymphoma

被引：0
|
作者：
Furtado, M. V. [1 ]
Rule, S. [1 ]
机构：
[1] Derriford Hosp, Dept Haematol, Plymouth PL6 8DH, Devon, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2012年 / 157卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
119
引用
收藏
页码：47 / 48
页数：2
相关论文
共 50 条
  • [1] Biomarkers of sensitivity and resistance to the BTK inhibitor PCI-32765 in mantle cell lymphoma
    Balasubramanian, Sriram
    Chen, Jun
    Crowley, Richard
    Buggy, Joseph J.
    CANCER RESEARCH, 2012, 72
  • [2] Zanubrutinib: a new BTK inhibitor for treatment of relapsed/refractory mantle cell lymphoma
    Weaver, A. N.
    Jimeno, A.
    DRUGS OF TODAY, 2020, 56 (08) : 531 - 539
  • [3] Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors
    Burkart, Madelyn
    Karmali, Reem
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (03):
  • [4] Activity of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Mantle Cell Lymphoma (MCL) Identifies Btk As a Novel Therapeutic Target
    Ponader, Sabine
    Balasubramanian, Sriram
    Pham, Lan V.
    Chen, Jun
    Tamayo, Archito T.
    Wang, Michael
    O'Brien, Susan
    Wierda, William G.
    Keating, Michael J.
    Ford, Richard J.
    Burger, Jan A.
    BLOOD, 2011, 118 (21) : 1576 - 1576
  • [5] Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
    Wang, Michael L.
    Rule, Simon
    Martin, Peter
    Goy, Andre
    Auer, Rebecca
    Kahl, Brad S.
    Jurczak, Wojciech
    Advani, Ranjana H.
    Romaguera, Jorge E.
    Williams, Michael E.
    Barrientos, Jacqueline C.
    Chmielowska, Ewa
    Radford, John
    Stilgenbauer, Stephan
    Dreyling, Martin
    Jedrzejczak, Wieslaw Wiktor
    Johnson, Peter
    Spurgeon, Stephen E.
    Li, Lei
    Zhang, Liang
    Newberry, Kate
    Ou, Zhishuo
    Cheng, Nancy
    Fang, Bingliang
    McGreivy, Jesse
    Clow, Fong
    Buggy, Joseph J.
    Chang, Betty Y.
    Beaupre, Darrin M.
    Kunkel, Lori A.
    Blum, Kristie A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (06): : 507 - 516
  • [6] Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy
    McCulloch, Rory
    Visco, Carlo
    Eyre, Toby A.
    Frewin, Rebecca
    Phillips, Neil
    Tucker, David L.
    Quaglia, Francesca M.
    McMillan, Annabel
    Lambert, Jonathan
    Crosbie, Nicola
    Rule, Simon
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (04) : 684 - 688
  • [7] UPDATED INTERIM RESULTS OF AN INTERNATIONAL, MULTICENTER, PHASE 2 STUDY OF IBRUTINIB (PCI-32765) IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA
    Rule, S.
    Wang, M.
    Martin, P.
    Auer, R.
    Kahl, B.
    Jurczak, W.
    Advani, R.
    Romaguera, J.
    Williams, M.
    Barrientos, J.
    Chmielowska, E.
    Radford, J.
    Stilgenbauer, S.
    Troung, V.
    McGreivy, J.
    Clow, F.
    Beaupre, D.
    Kunkel, L.
    Goy, A.
    Blum, K.
    HAEMATOLOGICA, 2013, 98 : 489 - 489
  • [8] Pirtobrutinib: A novel non-covalent BTK inhibitor for the treatment of adults with relapsed/refractory mantle cell lymphoma
    Davis, Dominique D.
    Ohana, Zahava
    Pham, Huy M.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (01) : 182 - 188
  • [9] The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study
    Fowler, Nathan
    Sharman, Jeff Porte
    Smith, Sonali M.
    Boyd, Thomas
    Grant, Barbara
    Kolibaba, Kathryn S.
    Furman, Richard R.
    Buggy, Joseph
    Loury, David
    Hamdy, Ahmed
    Advani, Ranjana
    BLOOD, 2010, 116 (21) : 425 - 425
  • [10] Pirtobrutinib in covalent BTK-inhibitor pre- treated relapsed/refractory (R/R) Mantle Cell Lymphoma
    Fileni, Caroline
    Sarkozy, Clementine
    BULLETIN DU CANCER, 2023, 110 (10) : 988 - 990
12345